Albert Cook, MD
Neurology · Johns Creek, GANPI 1891729430
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $259,815 of the $330,969 with a category attached, or 78.5%. CSL Behring accounts for 71.3% of it on its own, with 36 other manufacturers making up the rest. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 724 payments — averaging $457.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$236K
- Argenx US, Inc.$79K
- Pfizer$5K
- Novartis$3K
- Abbott$854
- AstraZeneca$788
- plus $6K from 31 others
What the payments were for
- Consulting fees$8,0772%
- Speaking & faculty fees$259,81579%
- Travel & lodging$50,10815%
- Food & beverage$12,7804%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 363 | $236,084 |
| Argenx US, Inc. | 99 | $78,653 |
| Pfizer | 12 | $5,213 |
| Novartis | 46 | $3,251 |
| Abbott | 8 | $854 |
| AstraZeneca(2 entities) | 18 | $788 |
| Biogen | 5 | $620 |
| Teva Pharmaceuticals USA, Inc. | 17 | $582 |
| Sanofi | 10 | $580 |
| AbbVie | 10 | $534 |
| E.r. Squibb & Sons, L.L.C. | 5 | $517 |
| Johnson & Johnson(2 entities) | 5 | $463 |
| EMD Serono, Inc. | 16 | $395 |
| UCB, Inc. | 17 | $327 |
| Amgen | 12 | $322 |
| Amneal Pharmaceuticals LLC | 10 | $277 |
| Globus Medical | 1 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $181 |
| Grifols USA, LLC | 8 | $161 |
| Eisai Inc. | 9 | $144 |
| Upsher-smith Laboratories LLC | 7 | $130 |
| Vanda Pharmaceuticals Inc. | 5 | $113 |
| MDD US Operations, LLC | 6 | $111 |
| Adamas Pharmaceuticals, Inc. | 5 | $95 |
| Lundbeck LLC | 2 | $51 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $36 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Livanova USA, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hizentra$231,505
- VYVGART$58,886
- VYVGART HYTRULO$16,489
- PANZYGA$5,000
- AIMOVIG$2,707
- TYSABRI$600
- Neuromodulation Dspsbls and Accs$365
- ZEPOSIA$362
- UBRELVY$350
- ULTOMIRIS$270
- Infinity DBS Pulse Generators$245
- AUBAGIO$240
- Mavenclad$231
- INDEPENDENCE$185
- AJOVY$121
- AUSTEDO$113
- Ponvory$106
- CREXONT$102
How this compares
$330,969 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 12 | $91,900 |
| AustedoDeutetrabenazine | 11 | $56,050 |
| RytaryCarbidopa/Levodopa | 20 | $26,617 |
| OngentysOpicapone | 15 | $15,481 |
| Rasagiline Mesylate | 30 | $10,163 |
| Mycophenolate Mofetil | 23 | $6,499 |
| Lacosamide | 25 | $6,443 |
| Gabapentin | 144 | $3,549 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 40 | $2,690 |
| Pyridostigmine Bromide | 27 | $2,488 |
| Memantine Hcl | 45 | $2,202 |
| Selegiline Hcl | 19 | $2,034 |
| Pregabalin | 52 | $2,016 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 81 | $1,711 |
| Primidone | 43 | $1,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $620 | $91,90012 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $582 | $56,05011 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $277 | $35,60470 claims |
| Upsher-smith Laboratories LLCTopiramate | $130 | $58636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Johns Creek
- Mark HarrisJohns Creek$59K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Dinesh RajuLawrenceville$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.